Comprehensive Pancreatic Cancer Biomarker Analysis of Fecal and Blood Metabolites and Gut Microbiota

Comprehensive Pancreatic Cancer Biomarker Analysis of Fecal and Blood Metabolites and Gut Microbiota - Pancreatic Cancer Biomarker discovery study in Feces and Blood

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054592

Enrollment

Registered

2024-06-06

Start date

2024-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer patient, Patients without pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: More than 20 years old and less than 90 years old Pancreatic cancer group: Patients diagnosed with resectable pancreatic cancer or resectable borderline pancreatic cancer Control group: Patients without pancreatic cancer

Exclusion criteria

Exclusion criteria: (1) pancreatic cancer patients previously treated (2) Patients with severe intestinal diseases (3) Patients who have undergone bowel cleansing within 3 months (4) Patients who have received antibiotics or laxatives within 3 months (5) individuals who did not accept informed consent (6) Patients who cannot collect the necessary volume of sample for analysis (7) unsuitable individuals for this clinical study

Design outcomes

Primary

Measure	Time frame
To search for new biomarkers specific to pancreatic cancer, based on the results of comprehensive metabolite and gut microbiota analysis obtained from the samples in this study.	—

Countries

Japan

Contacts

Public ContactTsuyoshi Osawa

The University of Tokyo Research Center for Advanced Science and Technology

osawa@lsbm.org03-5452-5025

Outcome results